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Drug-induced Long QT Interval 
(Full update October 2007; last modified October 2009) 
 
Drugs That Prolong the QT Interval and/or Induce Torsades de Pointes*,1 
Antiarrhythmics 
Amiodarone (Cordarone)a,b,c,d 
Dofetilide (Tikosyn)a,b,c,d 
Ibutilide (Corvert)a,b,c,d 
Procainamide (Procan, Pronestyl)a,b,c,d 
Sotalol (Betapace)a,b,c,d 
Disopyramide (Norpace)a,b,c,d 
Flecainide (Tambocor)a,b,c,d 
Mexiletine (Mexitil)c,d 
Quinidine a,b,c,d 
Antibiotics/Anti-infectives 
Azithromycin (Zithromax, Zmax)a,b,c,d 
Clarithromycin (Biaxin)a,b,c,d 
Gatifloxacin (Tequin)a,d-off market 
Grepafloxacin (Raxar)a,d-off market 
Lomefloxacin (Maxaquin)a,b,d-off market 
Norfloxacin (Noroxin)a,b 
Sparfloxacin (Zagam)a,b,c,d-off market 
Trimethoprim-Sulfamethoxazole (Bactrim)c 
Ciprofloxacin (Cipro)a,b,c,d 
Erythromycina,b,c,d 
Gemifloxacin (Factive)a,b,d 
Levofloxacin (Levaquin)a,b,c,d 
Moxifloxacin (Avelox)a,b,c,d 
Ofloxacin (Floxin)a,b,c,d 
Telithromycin (Ketek)a,b,d 
 
Anticancer 
Arsenic trioxide (Trisenox)a,b,c,d 
Nilotinib (Tasigna)a,b,d 
Tamoxifen (Nolvadex)a,d 
Dasatinib (Sprycel)a 
Sunitinib (Sutent)a,b,d 
Antidepressants 
Amitriptyline (Elavil, Endep)c,d 
Citalopram (Celexa)a,b,c,d 
Doxepin (Sinequan)c,d 
Imipramine (Tofranil)c,d 
Paroxetine (Paxil)b,d 
Sertraline (Zoloft)a,b,d 
Venlafaxine (Effexor)a,b,d 
Amoxapined 
Desipramine (Norpramin)a,c,d 
Fluoxetine (Prozac)a,b,c,d 
Nortriptyline (Pamelor, Aventyl)d 
Protriptyline (Vivactil)d 
Trimipramine (Surmontil)d 
Antihistamines 
Astemizole (Hismanal)-off market Terfenadine (Seldane)-off market 
Antiemetics/Antinausea 
Dolasetron (Anzemet)a,d 
Droperidol (Inapsine)a,b,c,d 
Ondansetron (Zofran)a,d 
Domperidone (Motilium)c,d 
Granisetron (Kytril)d 
ADHD Agents 
Amphetamine/dextroamphetamine (Adderall)d 
Dexmethylphenidate (Focalin)d 
Methylphenidate (Ritalin, Concerta)d 
Atomoxetine (Strattera)a,d 
Dextroamphetamine (Dexedrine)d 
 
Antifungals 
Fluconazole (Diflucan)a,b,c,d 
Ketoconazole (Nizoral)c,d 
Itraconazole (Sporanox)a,b,d 
Voriconazole (VFend)a,b,c,d 
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Antipsychotics** 
Aripiprazole (Abilify)a 
Chlorpromazine (Thorazine)c,d 
Haloperidol (Haldol)a,b,c,d 
Mesoridazine (Serentil)a,d 
Pimozide (Orap)a,c,d 
Risperidone (Risperdal)a,b,c,d 
Ziprasidone (Geodon)a,b,c,d 
Asenapine (Saphris)a,d 
Clozapine (Clozaril)c,d 
Iloperidone (Fanapt)a,b,d 
Paliperidone (Invega)a,d 
Quetiapine (Seroquel)a,c,d 
Thioridazine (Mellaril)a,b,c,d 
 
Appetite Suppressants 
Fenfluramine (Pondimin)d-off market 
Sibutramine (Meridia)d 
 
Phentermine (Fastin)d 
 
 
Bronchodilators 
Albuterol (Proventil, Ventolin)a,d 
Epinephrine (Bronkaid, Primatene)d 
Levalbuterol (Xopenex)a,d 
Salmeterol (Serevent)a,d 
Ephedrined 
Isoproterenol (Isuprel)d 
Metaproterenol (Alupent)d 
Terbutalinea,d 
Cardiac Agents, Misc. 
Bepridil (Vascor)a,b,c,d 
Dopamined 
Moexipril/HCTZ (Uniretic)a,d 
Norepinephrine (Levophed)d 
Dobutamine (Dobutrex)c,d 
Isradipine (Dynacirc)a,d 
Nicardipine (Cardene)a,d 
Ranolazine (Ranexa)a,d 
Decongestants 
Phenylephrine (Neo-Synephrine)d 
 
Pseudoephedrine (PediaCare, Sudafed)d 
GI Stimulant 
Cisapride (Propulsid)a,b,c,d -restricted use 
 
 
Miscellaneous 
Alfuzosin (Uroxatral)a,d 
Chloral Hydratec,d 
Cocainec,d 
Foscarnet (Foscavir)a,d  
Galantamine (Razadyne)a,b 
Indapamide (Lozol)c,d 
Lithium (Lithobid, Eskalith)a,d  
Midodrine (ProAmatine)d 
Pentamidine (Pentam, NebuPent)a,b,c,d 
Ritodrine (Yutopar)d-off market 
Tacrolimus (Prograf)a,b,c,d  
Tolterodine (Detrol)d 
Amantadine (Symmetrel)d 
Chloroquine (Arelan)a,c,d 
Felbamate (Felbatol)b,d 
Fosphenytoin (Cerebyx)a,d 
Halofantrine (Halfan)a,b,c,d 
Levomethadyl (Orlaam)a,d-off market 
Methadone (Dolophine)a,b,c,d 
Octreotide (Sandostatin)d 
Probucol (Lorelco)a,b,d-off market 
Solifenacin (Vesicare)a,d 
Tizanidine (Zanaflex)a,d 
Vardenafil (Levitra)a,d 
 
a QT prolongation is mentioned in the FDA-approved labeling. 
b The FDA-approved labeling includes mention of cases or a risk of torsades de pointes. 
c There are case reports of torsades de pointes in the medical literature. 
d A drug to be avoided in diagnosed or suspected long QT syndrome (LQTS) 
* List may not include all marketed drugs with QT prolongation/torsades risk. 
**QT prolongation with use of olanzapine (Zyprexa) has been reported in the medical literature, but is not 
mentioned as an adverse effect in FDA-approved labeling.6 
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Background 
Long QT interval syndrome (LQTS) can be 
responsible for sudden loss of consciousness and 
death.  It is characterized by QT prolongation with 
tachycardia.  Patients with LQTS are at risk for the 
arrhythmia known as torsades de pointes.  
Symptoms range from syncope where the torsades 
stop abruptly to cardiac arrest when it results in 
ventricular fibrillation.2  LQTS can be an inherited 
or acquired condition.  Drug-induced LQTS is the 
most common form of acquired syndrome.3   
In recent years drug-induced prolongation of 
QT interval has resulted in product removal from 
the market or “Black Box” warnings being required 
in product prescribing information.  Astemizole 
(Hismanal), grepafloxacin (Raxar), and terfenadine 
(Seldane) are examples of products which have 
been removed.   Cisapride (Propulsid), amiodarone 
(Cordarone), droperidol (Inapsine), itraconazole 
(Sporanox), and thioridazine (Mellaril) are some of 
the products with “Black Box” warnings associated 
with QT prolongation.  These and other products 
must be used with caution in patients with 
suspected or diagnosed congenital LQTS.   
Additionally, the combination of two or more 
drugs with the potential for prolonged QT intervals 
can have an additive or synergistic effect to 
prolong myocardial repolarization.  A single 
hepatically metabolized medication that prolongs 
the QT interval when prescribed with another drug 
that increases the plasma concentration of the first 
drug presents a similar danger.  Most often the 
interacting drug is an inhibitor of hepatic 
metabolism mediated by the cytochrome P-450 
isoenzyme 3A4 (CYP3A4).  A recent article has 
described an increased rate of sudden death 
associated with oral erythromycin, a hepatically 
metabolized LQTS-associated drug, in combination 
with either diltiazem or verapamil, both CYP3A4 
inhibitors.4 
 
Citation 
Ray, WA, Murray KT, Meredith S, et al.  Oral 
erythromycin and the risk of sudden death from 
cardiac causes.  N Engl J Med 2004 351;1089-96. 
 
Methods 
A Tennessee Medicaid cohort was studied that 
included 1,249,943 person-years of follow-up and 
1,476 cases of confirmed sudden death from 
cardiac causes in a community setting.  The study 
sought to determine cardiac-caused death 
associated with erythromycin alone and also with 
concomitant use of erythromycin plus potential 
inhibitors of CYP3A4.  These inhibitors included 
azole antifungal agents, calcium-channel blockers 
(diltiazem and verapamil), and troleandomycin.  
Erythromycin is metabolized by CYP3A4 and is 
associated with LQTS.  Amoxicillin, which has 
similar indications as erythromycin but is not 
associated with LQTS, was used as a comparative 
agent.   
 
Results 
The multivariate adjusted sudden death rate 
from cardiac causes among patients currently using 
erythromycin was twice as high as the rate among 
those not using any study antibiotic medications 
(incidence-rate ratio, 2.01: 95% confidence 
interval, 1.08 to 3.75; P= 0.03).  There was no 
significant increase in sudden death risk among 
former erythromycin users (incidence-rate ratio, 
0.89; 95% confidence interval, 0.l72 to 1.09; 
P=0.26) or current users of amoxicillin (incidence-
rate ratio, 1.18; 95% confidence interval, 0.59 to 
2.36; P=0.65).  The sudden cardiac-cause, adjusted 
death rate was five times as high among those 
concurrently using the CYP3A4 inhibitors, 
diltiazem or verapamil, with erythromycin as that 
among those who used neither CYP3A4 inhibitors 
nor study antibiotics (incidence-rate ratio, 5.35; 
95% confidence interval, 1.72 to 16.64; P=0.004).  
There was no increased risk of sudden death 
among those concurrently using amoxicillin and 
CYP3A4 inhibitors or those currently using any of 
the study antibiotics who formerly used CYP3A4 
inhibitors.4 
 
Author Conclusion 
Concurrent use of erythromycin and strong 
CYP3A4 inhibitors should be avoided.4   
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Commentary 
Drugs that prolong the QT interval can of 
themselves increase the risk of sudden cardiac 
death.  Risk increases when two or more LQTS 
drugs are combined.  Further risk can occur when 
LQTS drugs (like erythromycin) are administered 
concurrently with strong inhibitors of CYP3A4 
[Evidence level B; clinical cohort study].  Levels of 
LQTS-associated drugs may dangerously increase 
when concomitantly administered with CYP3A4 
inhibitors and thus increase the risk of QT 
prolongation.  All of these should be avoided, 
especially in known or suspected LQTS patients.5 
Identification of LQTS patients is suggested as 
a preventative measure.  An electrocardiogram 
(ECG, EKG), exercise ECG, or a “Holter” ECG 
can identify LQTS.  Indicators of LQTS include 
unexplained syncope that occurs during or just 
after physical exertion, emotional excitement or 
sudden auditory arousal, and also family history of 
unexplained fainting or sudden death.2 
Risk cofactors for LQTS or torsades de pointes 
include hypokalemia, hypomagnesemia, 
bradycardia, and heart failure.  Women have a 
higher risk of drug-induced torsades because they 
have longer QT intervals than men. Other groups 
also at risk include the elderly, psychiatric patients, 
and patients with anorexia nervosa.1-3  
 
 
Users of this document are cautioned to use their own 
professional judgment and consult any other necessary 
or appropriate sources prior to making clinical 
judgments based on the content of this document.  Our 
editors have researched the information with input from 
experts, government agencies, and national 
organizations.  Information and Internet links in this 
article were current as of the date of publication. 
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Levels of Evidence 
In accordance with the trend towards Evidence-Based 
Medicine, we are citing the LEVEL OF EVIDENCE 
for the statements we publish. 
 
Level Definition 
A High-quality randomized controlled trial (RCT) 
 High-quality meta-analysis (quantitative 
systematic review) 
B Nonrandomized clinical trial 
 Nonquantitative systematic review 
 Lower quality RCT 
 Clinical cohort study 
 Case-control study 
 Historical control 
 Epidemiologic study 
C Consensus 
 Expert opinion 
D Anecdotal evidence 
In vitro or animal study 
Adapted from Siwek J, et al.  How to write an evidence-based clinical 
review article.  Am Fam Physician 2002;65:251-8. 
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